Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Metadata
Title
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Authors
William H. Ludlam
Lowell Anthony
Publication date
01-10-2011
Publisher
Springer Healthcare Communications
Published in
Advances in Therapy / Issue 10/2011
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-011-0062-9

Other articles of this Issue 10/2011

Advances in Therapy 10/2011 Go to the issue

Original Research

Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography/magnetic resonance angiography

Original Research

Long-term safety and efficacy of the recombinant human growth hormone omnitrope® in the treatment of Spanish growth hormone deficient children: Results of a phase III study

Original Research

The “MESACA” study: Methylsulfonylmethane and boswellic acids in the treatment of gonarthrosis

Original Research

Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors

Original Research

Pharmacokinetic pilot study of the antiangiogenic activity of standardized platycodi radix

Review

Unapproved drugs in the united states and the food and drug administration

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits